[68Ga]Ga-SSO120 PET/CT Imaging in Pediatric Patients with Neuroblastoma: Biodistribution and Whole-Body Radiation Dosimetry

The clinical standard for neuroblastoma detection is based on targeting the norepinephrine transporter with [123I]MIBG, which has several challenges. Imaging the somatostatin receptor (SSTR) is a strong alternative. In contrast to standard DOTATATE, SSTR antagonist imaging with [68Ga]Ga-satoreotide trizoxetan ([68Ga]-SSO120) can potentially improve lesion detection as it targets both active and inactive SSTRs. We present the biodistribution and radiation exposure results of [68Ga]Ga-SSO120 PET/CT imaging in pediatric patients with neuroblastoma.

Methods

Patients age 3-7 y with stage 4 neuroblastoma received 2 MBq/kg of [68Ga]Ga-SSO120, followed by a 60-min dynamic scan and a static PET/CT scan. SUV normalized to lean body mass (SULmax, SULmean, SULpeak) and time-activity curves were measured for suspected lesions and various tissue compartments. Tumor-to-liver and tumor-to-blood pool ratios were calculated. Radiation doses to various organs and the total-body effective dose were computed.